Amgen to fight USD 10bn tax bill

On the day the firm’s second quarter results are slated for release, Amgen also announces it will contest a double-digit billion-dollar tax bill issued by the US Internal Revenue Service.

Photo: Robert Galbraith/Reuters/Ritzau Scanpix

The US Internal Revenue Service, or IRS, has had its attention fixed on Boston-based biotech firm Amgen. In connection with the firm’s first quarterly report from April, Amgen said it had received a notice from the IRS stating that the firm had to pay USD 5.1bn plus interest in addition to a fine of around USD 2bn for missing tax payments, reports The Wall Street Journal on the day Amgen presents its second quarter report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs